Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
Abstract Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1) expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive biomarker for immunotherapy efficacy in patients with advanced non‐small‐cell lung cancer (NSCLC). Methods We employed a...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14767 |
| _version_ | 1811164971859443712 |
|---|---|
| author | Qing Zhou Xiangning Liu Ji Li Bing Tong Yan Xu Minjiang Chen Xiaoyan Liu Xiaoxing Gao Yuequan Shi Jing Zhao Wei Zhong Mengzhao Wang |
| author_facet | Qing Zhou Xiangning Liu Ji Li Bing Tong Yan Xu Minjiang Chen Xiaoyan Liu Xiaoxing Gao Yuequan Shi Jing Zhao Wei Zhong Mengzhao Wang |
| author_sort | Qing Zhou |
| collection | DOAJ |
| description | Abstract Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1) expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive biomarker for immunotherapy efficacy in patients with advanced non‐small‐cell lung cancer (NSCLC). Methods We employed a negative enrichment method to isolate CTCs. We identified PD‐L1 + CTCs as PD‐L1+/4′,6‐diamidino‐2‐phenylindole (DAPI)+/CD45‐circulating tumor cells through an immunofluorescence method. Tumor tissue PD‐L1 expression was determined by immunohistochemical staining. The correlation between CTC PD‐L1 expression and patients' prognostic features was estimated through the Kaplan–Meier method. Results CTCs released a higher detection rate of PD‐L1 expression than tumor tissues (53.0% vs. 42.1%). No correlation was observed between them. Forty‐nine NSCLC patients received anti‐PD‐1/PD‐L1 immunotherapy (three with combined anti‐PD‐1/PD‐L1 and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), two with four cycles of combined immune checkpoint inhibitors [ICIs] plus chemotherapy and ICI monotherapy for maintenance). Patients with PD‐L1 expression on tissue or CTCs had a median progression‐free survival (mPFS) of 5.6 months (n = 36, 95% confidence interval [CI] 3.6–7.5 months), significantly longer than those without PD‐L1 detection (n = 9, mPFS of 1.4 months, 95% CI 1.3–1.5 months, log‐rank p = 0.032). The multivariable Cox proportional‐hazard model suggested that the tissue or CTC PD‐L1 expression was associated with a lower risk of progression (hazard ratio 0.45, 95% CI 0.21–0.98, p = 0.043). Conclusions CTCs and tumor tissues reveal heterogeneous expression of PD‐L1 in NSCLC patients. Patients with baseline PD‐L1 expression on CTCs or tissue showed prolonged mPFS and may help to identify the subsets of patients who potentially benefit from immunotherapy. |
| first_indexed | 2024-04-10T15:29:57Z |
| format | Article |
| id | doaj.art-33ac306df8ef419f88997f9415254a1d |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-10T15:29:57Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-33ac306df8ef419f88997f9415254a1d2023-02-14T02:01:34ZengWileyThoracic Cancer1759-77061759-77142023-02-0114547047810.1111/1759-7714.14767Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancerQing Zhou0Xiangning Liu1Ji Li2Bing Tong3Yan Xu4Minjiang Chen5Xiaoyan Liu6Xiaoxing Gao7Yuequan Shi8Jing Zhao9Wei Zhong10Mengzhao Wang11Department of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pathology Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences Beijing ChinaAbstract Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1) expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive biomarker for immunotherapy efficacy in patients with advanced non‐small‐cell lung cancer (NSCLC). Methods We employed a negative enrichment method to isolate CTCs. We identified PD‐L1 + CTCs as PD‐L1+/4′,6‐diamidino‐2‐phenylindole (DAPI)+/CD45‐circulating tumor cells through an immunofluorescence method. Tumor tissue PD‐L1 expression was determined by immunohistochemical staining. The correlation between CTC PD‐L1 expression and patients' prognostic features was estimated through the Kaplan–Meier method. Results CTCs released a higher detection rate of PD‐L1 expression than tumor tissues (53.0% vs. 42.1%). No correlation was observed between them. Forty‐nine NSCLC patients received anti‐PD‐1/PD‐L1 immunotherapy (three with combined anti‐PD‐1/PD‐L1 and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), two with four cycles of combined immune checkpoint inhibitors [ICIs] plus chemotherapy and ICI monotherapy for maintenance). Patients with PD‐L1 expression on tissue or CTCs had a median progression‐free survival (mPFS) of 5.6 months (n = 36, 95% confidence interval [CI] 3.6–7.5 months), significantly longer than those without PD‐L1 detection (n = 9, mPFS of 1.4 months, 95% CI 1.3–1.5 months, log‐rank p = 0.032). The multivariable Cox proportional‐hazard model suggested that the tissue or CTC PD‐L1 expression was associated with a lower risk of progression (hazard ratio 0.45, 95% CI 0.21–0.98, p = 0.043). Conclusions CTCs and tumor tissues reveal heterogeneous expression of PD‐L1 in NSCLC patients. Patients with baseline PD‐L1 expression on CTCs or tissue showed prolonged mPFS and may help to identify the subsets of patients who potentially benefit from immunotherapy.https://doi.org/10.1111/1759-7714.14767circulating tumor cellsimmunotherapynon‐small‐cell lung cancerprogrammed death‐ligand 1 |
| spellingShingle | Qing Zhou Xiangning Liu Ji Li Bing Tong Yan Xu Minjiang Chen Xiaoyan Liu Xiaoxing Gao Yuequan Shi Jing Zhao Wei Zhong Mengzhao Wang Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer Thoracic Cancer circulating tumor cells immunotherapy non‐small‐cell lung cancer programmed death‐ligand 1 |
| title | Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer |
| title_full | Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer |
| title_fullStr | Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer |
| title_full_unstemmed | Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer |
| title_short | Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer |
| title_sort | circulating tumor cells pd l1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non small cell lung cancer |
| topic | circulating tumor cells immunotherapy non‐small‐cell lung cancer programmed death‐ligand 1 |
| url | https://doi.org/10.1111/1759-7714.14767 |
| work_keys_str_mv | AT qingzhou circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT xiangningliu circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT jili circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT bingtong circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT yanxu circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT minjiangchen circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT xiaoyanliu circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT xiaoxinggao circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT yuequanshi circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT jingzhao circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT weizhong circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer AT mengzhaowang circulatingtumorcellspdl1expressiondetectionandcorrelationoftherapeuticefficacyofimmunecheckpointinhibitioninadvancednonsmallcelllungcancer |